Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  Nicola.

Published byMaria Forsberg Modified over 5 years ago

Similar presentations

Presentation on theme: "P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  Nicola."— Presentation transcript:

1 P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  Nicola Wyatt, Linda Hogarth, Dianne Turner, Miranda Patterson, David Jamieson, Fiona Black, Claire Hutton, Paula Mulvenna, Tim Simmons, Alexander Bradshaw, Claire Kolenda, Craig Parker, Carmen Martin-Ruiz, Alastair Greystoke  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S829-S830 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S829-S830DOI: (10. 1016/j. jtho
Copyright © Terms and Conditions

Download ppt "P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  Nicola."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
P2.01-021 miRNA Deep Sequencing of Early-Stage Lung Cancer Patients to Evaluate the Dynamic Change of Circulating Biomarkers in Response to Surgery  Daniela.

P miRNA Deep Sequencing of Early-Stage Lung Cancer Patients to Evaluate the Dynamic Change of Circulating Biomarkers in Response to Surgery  Daniela.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis  Shaohua Lu, Takashi.
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)  Vincent Lam, Hai Tran,

P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)  Vincent Lam, Hai Tran,
P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)  Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.

P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)  Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
P2.01-007 Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,
Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)

Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)
P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

Similar presentations

Ads by Google